• "Workshop on Solutions for the Dangerous Situation of Uyghurs Today" hold at Fatih Sultan Mehmet University on 25 August 2018
You Are Here: Home » Famous Uyghurs » Dr. Rishat Abbas Borhan

Dr. Rishat Abbas Borhan

BRIEF BIOGRAPHY

Dr. Rishat Abbas-Borhan (Richat Abbas) is a Director and Clinical Pharmacology Lead at Pfizer.  Fellow of American College of Clinical Pharmacology.

He received his PhD in Pharmaceutical Sciences , with focus on pharmacokinetics/ pharmacodynamics, from the Ohio State University, USA, in 1994.  For more than 20 years since 1994, Dr. Abbas-Borhan worked on research projects in government research laboratories, Bio-Tech and in the area of pharmaceutical research-development (R&D) in the United States.  He conducted  innovative research on development of new medicines from preclinical to clinical, as he held  positions of increasing responsibility (ie., he was involved in more than 30 clinical Phase 1/clin pharm studies, and more than 30 clinical phases 2/3/4 studies for oncology and other candidate drugs), and contributed to the research-development of new cardiovascular (PLETALÒ), central nervous system (AbilifyÒ), diabetes (Oral Insulin – in R&D) and anti-cancer drugs (TarcevaÒ  for treatment of lung cancer and BosulifÒ for treatment of CML – blood cancer). More recently, he has been involved in various innovative clinical studies and especially in the US-FDA approval of taliglucerase alfa (ELELYSOTM for long-term enzyme replacement therapy) in 2014 and of QuilliChew ERTM (for CNS disease) (Pfizer) in 2015. Additionally, Dr. Abbas-Borhan authored/co-authored over 150 peer-reviewed publications (which were published in prestigious journals such as, Clinical Cancer Research, International Journal of Cancer and Blood), presented at numerous conferences and have written abstracts for patents and book chapters..  He received a number of prestigious awards for research achievements, including Science & Technology Achievement Award from the U.S. Department of Defense, Scientific Achievement Award from the U.S. Department of the Air Force, Best Paper Award from the Society of Toxicology, Best Abstract (oral insulin) Award from the Diabetes Technologies Meeting, Exceptional Innovation/Achievement Award and Milestone Recognition Award for outstanding contribution to new anti-cancer drug research projects (2009), and the ‘2015 Quality Award’.  He is a member of the American Society of Clinical Pharmacology & Therapeutics, American College of Clinical Pharmacology, and American Association of Pharmaceutical Scientists.  Currently, he is serving as an invited peer reviewer for a number of international pharmaceutical journals, including the Journal of Clinical Pharmacology, Clinical Pharmacokinetics, the European Journal of Clinical Pharmacology and Acta Pharmacologica Sinica (Drug Research and Clinical Therapeutics).

 

Qisqiche Terjimehali

Doktur Rishat Abbas Borhan nowette Amerikidiki xelgharalik tibbi dora tetqiqat we tereqqi qildurush birleshme idarisi –– Pfizer de Ali Derijilik Tetqiqat Alimi we Tetqiqat Mudiri bolup rak ve bashqa kiselliri dora tetqiqati elip barmaqda. American College of Clinical Pharmacology ning Akademik.

Rishat Abbas 1989- yili Urumchidin Amerikigha oqushqa chiqip,  1994- yili Ohio Shitatliq Uniwersititida (The Ohio State University, USA) Tibbi Dora tetqiqat Ilmi boyiche Dokturluq Unwanigha erishken.  1994- yilidin 1996-yilighiche, Amerika Dolet Mudapie Ministirligi Hawa Armiyisining tetqiqat berkigi tejirbihanisida (Wright-Patterson Air Force Base, Dayton, OH, USA)  Doktur Ashdi Tetqiqati bilen shughullan’ghan.  1996- yilidin hazirghiqe bolghan Amerikadiki 20 yildin artuq tibbi dora tetqiqat hayatida, Rishat Abbas Amerikidiki Xelq’araliq Tibbi Dora tetqiqat merkezliride yingi dorilarni tetqiq we tereqqi qildurush sahiyeside zor unumluk tetqiqat xizmetliride bolghan we yuquri derijilik tetqiqat netijilerge irishken.

Rishat Abbas yingi dorilarni tetqiq qilish we tereqqi qildurush hemde ularni Kilinikiliq tetqiqat tejirbidin otkuzush jehetliride, dawamliq muhim mesuliyetlerni oz ustige ilip, alahide netijilerge irishti.  Bularning ichide: Rak Kiselligige shipa bolidighan yingi dora – TarcevaÒ (Opke raki) we BosulifÒ (qan raki), yurek-qan tomur kisellirige shipa bolidighan yingi dorr –  PLETALÒ, hemde nerwe kiselirige dewa  – AbilifyÒ larning tetqiqatigha kozge korunerlik tohpilerni qoshti.  U, hem,  neche qetim Amerika Dolet ministirlik we xelgharaliq pen-tetqiqat jemiyetlirining  teqdirleshliri we mukapatlashlirigha sazawer boldi.  Bularning ichide Amerika Dolet Mudapie Ministirligi (the U.S. Department of Defense) teripidin uninggha birilgen “Pen we Texnika Netije Mukapati” (Science and Technology Achievement Award), Amerika Hawa Armiye Bash Ishtabidin (the U.S. Department of Air Force) birilgen “Pen-tetqiqat Netije Mukapati” (Scientific Achievement Award) alahide kozge korunerliktur.  Uning maqalisi  heliq araliq “Zeherlik maddilar ilmi jemiyiti” (Society of Toxicology) teripidin  “munewwer eser” bolup bahalan’ghan.  Ve xelghara Diabetes kisili tetqiqqilish texnika yighinida yene maqalisi “Eng yaxshi mezmunluq maqale” bolup bahalan’ghan.  Yekinqi yilarde Uning rak kiselliklirini dawalash dora tetqiqat netijiliri “Pewqul’adde ijadiliqqaige netije” (Exceptional Innovation/Achievement Award) mukapatigha ve “alahide tunulush netije” (Milestone Recognition Award) mukapatlirigha irishken.

Hazirgha qeder u, 150 parchidin artuq tibbi dora tetqiqat ilmi maqalilerni xelghara tibbi dora tetqiqat jornallarda, we xelq’araliq tibbi dora tetqiqat yighinlarda (conference/congress) ilan qildi. Shundaqla yene dora ilmigha ait kitaplarning baplirini yizip chiqti.  U tibbi dora tetqiqat saheside yene 2 Amerika patent hoquqige irishti. Ve yeqinqi yilarde xelq’araliq tibbi dora tetqiqat ilmi jornalarning teklip qilin’ghan tehriri (peer reviewer) bolmaqda.

 

PUBLICATIONS (Peer Reviewed Articles):

  1. Floyd R. Sallee, Donna R. Palumbo, Richat Abbas, Sally A. Berry, Shivanand P. Puthli, and Kalyan K. Kathala. Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended-Release Oral Suspension for Attention Deficit Hyperactivity Disorder. Clinical Pharmacology in Drug Development. 2017, 00(0) 1–8. http://onlinelibrary.wiley.com/doi/10.1002/cpdd.366/full
  2. Chiho Ono, Poe-Hirr Hsyu, Richat Abbas, Cho-Ming Loi and Shinji Yamazaki. Application of Physiologically-Based Pharmacokinetic Modeling to Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions. ccc DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 45:390–398, April 2017. http://dx.doi.org/10.1124/dmd.116.074450
  3. Richat Abbas and Poe-Hirr Hsyu, Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib, Clin Pharmacokinet, October 2016, Volume 55, Issue 10, pp 1191–1204. DOI 10.1007/s40262-016-0391-6. http://link.springer.com/article/10.1007/s40262-016-0391-6
  4. Richat Abbas, PhD, Donna Palumbo, PhD, Faith Walters, PharmD, Heidi Belden, PharmD, Sally A. Berry, MD, PhD Single-Dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-Release Chewable Tablet Compared With Immediate-Release Methylphenidate Chewable Tablet. Clinical Therapeutics, Volume 38, Issue 5, May 2016, Pages 1151–1157 DOI information: 10.1016/j.clinthera.2016.02.026
  5. Richat Abbas, Glen Park, Bharat Damle, Raul Chertkoff, and Sari Alon. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease. Molecular Genetic and Metabolism. Research Article. PLOS ONE | DOI:10.1371/journal.pone.0128986 June 8, 2015. Volume 111, Issue 2, Pages S15–S16. http://dx.doi.org/10.1016/j.ymgme.2013.12.014
  6. Edward C. Li, Richat Abbas, Ira A. Jacobs and Donghua Yin. Considerations in the early development of biosimilar products. Drug Discovery Today May 2015, Volume 20, Supplement 2, Pages 1–10. http://dx.doi.org/10.1016/j.drudis.2014.12.017
  7. Richat Abbas, Joseph Boni, and Daryl Sonnichsen, Effect of Rifampin on the Pharmacokinetics of Bosutinib, a Dual Src/Abl Tyrosine Kinase Inhibitor, When Administered Concomitantly to Healthy Subjects Drug Metabol Personal Ther. 2015 Mar;30(1):57-63. doi: 10.1515/dmdi-2014-0026.
  8. Hsyu PH1, Mould DR, Abbas R, Amantea M. Population Pharmacokinetic and Pharmacodynamic Analysis of Bosutinib. Drug Metab Pharmacokinet. 29 (6) 1-8 (2014)
  9. Abbas R, Leister C, Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clinical Drug Investigation: Volume 33, Issue 8 (2013), Page 589-595
  10. Leena Gandhi, Rastislav Bahleda, Sara M Tolaney, Eunice L Kwak, James M Cleary, Shuchi S Pandya, Antoine Hollebecque, Richat Abbas, Revathi Ananthakrishnan, Anna Berkenblit, Mizue Krygowski, Yali Liang, Kathleen W Turnbull, Geoffrey I Shapiro, Jean-Charles Soria. Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors.  Journal of Clinical Oncology. 2014 Jan 10;32(2):68-75
  11. Richat Abbas, Stephan Chalon, Cathie Leister, Myriam El Gaaloul, Daryl Sonnichsen. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.  Cancer Chemother Pharmacol (2013) 71:123–132. DOI 10.1007/s00280-012-1987-7
  12. Chow, L.W.-C., Xu, B., Gupta, S., Freyman, A., Zhao, Y., Abbas, R., Vo Van, M.-L., Bondarenko, I. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. British Journal of Cancer: volume 108, issue 10, year 2013, pp. 1985 – 1993
  13. Richat Abbas, PhD; Cathie Leister, MS; Myriam El Gaaloul, PharmD; Stephan Chalon, MD, PhD; and Daryl Sonnichsen, PharmD. Ascending Single-Dose Study of the Safety Profile, Tolerability,and Pharmacokinetics of Bosutinib Coadministered With Ketoconazole to Healthy Adult Subjects. Clinical Therapeutics/Volume 34, Number 9, September 2012, pp 2011 – 2019.el.  doi: 10.1016/j.clinthera.2012.07.006. Epub 2012 Aug 9. PMID: 22884766 [PubMed – indexed for MEDLINE]
  14. Richat Abbas, Bruce A. Hug, Cathie Leister, Daryl Sonnichsen. A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Cancer Chemother Pharmacol. 2012 Jul;70(1):191-9. doi: 10.1007/s00280-012-1857-3. Epub 2012 Mar 15. PMID:22418773[PubMed – indexed for MEDLINE]
  15. Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol (2012) 69:221–227.
  16. Daud A, Krishnamurthi S, Saleh M, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith W. Phase 1 Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors.  Clinical Cancer Research. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16.
  17. Richat Abbas, Bruce A. Hug, Cathie Leister, Daryl Sonnichsen. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer. 2011 Nov 8. doi: 10.1002/ijc.27348.
  18. Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27;118(17):4567-4576.
  19. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.  Br J Clin Pharmacol. 2011 Apr;71(4):522-7. doi: 10.1111/j.1365-2125.2010.03845.x.
  20. Jorge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Dong-Wook Kim, Anna G. Turkina, Zhi-Xiang Shen, Ricardo Pasquini, H. Jean Khoury, Steven Arkin, Angela Volkert, Nadine Besson, Richat Abbas, Junyuan Wang,  Eric Leip, and Carlo Gambacorti-Passerini.  Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive CML patients with resistance or intolerance to imatinib Blood-2011-05-355594; Blood. volume 118, issue 17, year 2011, pp. 4567 – 4576
  21. Ramona F. Swaby, Zefei Jiang, Yan Sun, Khalil Zaman, Veronique Dieras, Charles Zacharchuk, Christine A. Powell, Richat Abbas, Mayuri Thakuria, Amy Freyman, and Kimberly L. Blackwell. A Phase I/II Study of Neratinib (HKI-272) in Combination with Trastuzumab for the Treatment of Patients with Advanced Breast Cancer; submission to the Journal of Clinical Oncology, 2011.
  22. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen Effect of Ketoconazole on the Pharmacokinetics (PK) of Bosutinib (SKI-606) in Healthy Subjects.  J Clin Pharmacol.  December 2011 vol. 51 no. 12 1721-1727.
  23. Bruce Hug, Richat Abbas, Cathie Leister, Jaime Burns, Daryl Sonnichsen. A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization in Healthy Adult Subjects.  Clinical Cancer Research. 16(15), 4016-4022, August 1, 2010.
  24. Harold J. Burstein, Yan Sun, Luc Y. Dirix, Zefei Jiang, Robert Paridaens, Antoinette R. Tan, Ahmad Awada, Anantbhushan Ranade, Shunchang Jiao, Gary Schwartz, Richat Abbas, Christine Powell, Kathleen Turnbull, Jennifer Vermette, Charles Zacharchuk, Rajendra Badwe. Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of Clinical Oncology, Vol 28, No 8 (March 10), 2010: pp. 1301-1307
  25. Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Munster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael J. Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, and Howard A. Burris. A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors.  Clin Cancer Res 2009 15: 2552-2558.
  26. Joseph Boni, Richat Abbas, Cathie Leister, Jaime Burns, Ronald Jordan, Mattew Hoffmann, William Demaio, and Bruce Hug. Disposition of Desipramine, a Sentisive Cytochrome P450 2D6 Substrate, When Coadministered with Intravenous Temsirolimus, Cancer Chemother Pharmacol (2009) 64:263-270.
  27. Grant Sellar, John D Alvarez, Frank Loganzo, Richat Abbas, Fred Immermann, Maha Karnoub, Giora Z Feuerstein, Michael E Burczynski, Christina M Coughlin. Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics.  Biomarkers in Medicine, April 2008, Vol. 2, No. 2, Pages 147-153.
  28. Gunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, Charles Zacharchuk, Luis Paz-Ares, Federico Rojo, Susan Quinn, Esther Casado, Ramon Salazar, Jordi Andreu, Richat Abbas, Chantal Lejeune, Irene Marimón, Jordi Andreu, Ulrike Ubbelohde, Hernan Cortes-Funes, Jose Baselga.  Phase I PK/PD study of EKB-569 – an irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase – in combination with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.  Clinical Cancer Research 14, 215, January 1, 2008.
  29. Laheru Dan; Croghan Gary; Bukowski Ronald; Rudek Michelle; Messersmith Wells; Erlichman Charles; Pelley Robert; Jimeno Antonio; Donehower Ross; Boni Joseph; Abbas Richat; Martins Patricia; Zacharchuk Charles; Hidalgo Manuel.  A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.   Clinical cancer research:  2008;14(17):5602-9.
  30. R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker. Effect of R411, a Dual 4/1-4/7 Integrin Antagonist Being Developed for Asthma, on the Activities of the Major Drug Metabolizing Enzymes After Oral Administration in Healthy Subjects.  Clinical Pharmacolgy & Therapeutics, Vol. 75, No.2, p-79, 2004.
  31. M Kidron, S Dinh, Y Menachem, R Abbas, B Variano, M Goldberg, E Arbit, H Bar-On. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabetic Medicine 05/2004; 21(4):354–357. [PubMed]
  32. Richat Abbas, Scott Fettner, Myriam Riek, Sunita Bulsara, Michael Pantze, Marta Hamilton, Paul Frohna, and Ashok Rakhit A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, TarcevaTM, in healthy subjects.   Proc Am Soc Clin Oncol 22: page 137, a-548, 2003
  33. Kapitza, E. Arbit, R. Abbas, M. Goldberg, M. Hompesch, L. Heinemann, T. Heise, Oral Insulin: Proof of concept in type 2 diabetic patients. Diabetes. 52-S.1. A37, 2003.
  34. Ashok Rakhit, Scott Fettner, Stephen Davis, Richat Abbas, Flavio De Rosa, Ulrich Brennscheidt, Chis Twelves and Jose Baselga. Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients.  European Journal of Cancer Supplements; Vol. 1, No. 5, p-S115 Sept. 2003.
  35. Ashok Rakhit, Scott Fettner, Myriam Riek, Stephen Davis, Marta Hamilton, Paul Frohna, Richat Abbas. Clinical pharmacokinetics of erlotinib in healthy subjects. European Journal of Cancer Supplements; Vol. 1, No. 5, p-S168, Sept. 2003.
  36. Zhongping John Lin, Richat Abbas , Lorraine M. Rusch and Linyee Shum – Development and Validation of a Sensitive LC-MS/MS Method for the Determination of Cromolyn in Human Plasma, Journal of Chromatography B 788 (2003) 159-166
  37. Richat Abbas, Andrea Leone-Bay, Rajesh Agawal, Shingai Majuru, Paul Rolan, Cyril Clarke, Colin Scott, Ehud Arbit¬, Robert A. Baughman – Oral Insulin: Pharmacokinetics and Pharmacodynamics of Human Insulin Following Oral Administration of an Insulin/Delivery Agent Capsule in Healthy Volunteers. 2002, Volume 51, A48, S. 2.
  38. Richat Abbas, Robert A. Baughman, S. De Bruyn2, Donald Sarubbi, and Ehud Arbit – Oral Cromolyn: Pharmacokinetics of Cromolyn Sodium Delivered Orally in Healthy Volunteers. Allergy Vol. 57, S73, 338, 2002
  39. Richat Abbas, Rajesh Agarwal, Terry Rivera-Schaub, Andrea Leone-Bay, Kiran Chaudhary, and Robert A. Baughman – Evaluation of the Effect of Three Different Oral Heparin/SNAC Formulations on Pharmacokinetics (PK) of Heparin Following Oral Administration in Healthy Subjects.  Sci Vol. 4, No. 4, R621, 2002.
  40. Richat Abbas, A.Chaouki Zerouala, and Robert A. Baughman. PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SNAD/HEPARIN IN RHESUS MONKEYS. “Drug Metabolism Review” Vol. 33, 400, 2001.
  41. Richat Abbas, Alda Pombo-Gentile, and Robert A. Baughman. Absolute bioavailability of SNAD and Pharmacokinetics of SNAD/heparin in rats.  “Drug Metabolism Review” Vol. 33, 124, 2001.
  42. Lorraine M. Rusch, Richat Abbas, Catherina M. O’Shaughnessy, Liangfu Chen, and Robert A. Baughman. Interspecies Comparison of SNAC and SNAD IN VITRO  PLASMA PROTEIN BINDING.  “Drug Metabolism Review” Vol. 33,  233, 2001.
  43. Catherina M. O’Shaughnessy, Lorraine M. Rusch, Richat Abbas, Liangfu Chen and Robert A. Baughman. IN VITRO EVALUATION OF SNAC INTERACTION WITH HUMAN CYP450 ISOENZYMES.   “Drug Metabolism Review” Vol. 33, 381, 2001.
  44. Richat Abbas, Gregory Osgood, Terry Rivera-Schaub, James C. Kisicki, and Robert A. Baughman. A Clinical Drug-interaction Study to Evaluate Effect of Antacid Pre-treatment on the Absorption of Heparin and its Delivery Agent, SNAC, Following Oral Administration in Healthy Subjects. Pharm. Res. Vol. 21, No., pp. s. 2001.
  45. Richat Abbas, Andrea Leone-Bay, Terry Rivera-Schaub, Shingai Majuru, James C. Kisicki, and Robert A. Baughman. An Open-label, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SNAD, an Oral Heparin Delivery Agent, when Administered Orally as SNAD Tablets or Heparin/SNAD Tablets to Healthy Male Volunteers. Pharm. Res. Vol. 21, No.,  s-  2001.
  46. Abbas, R., Chow, C. P., Browder, N. , Thacker, D., Bramer, S. L., Fu, C. H. J., Forbes, W., Odomi, M. and Flockhart, D.A. In vitro Metabolism and Interaction of  Cilostazol  with  Human Hepatic Cytochrome P450 Isoforms. Human & Experimental Toxicology. 19(3). March, 2000. 178-184.
  47. Lash, L. H., Putt, D. A. Brashear, W. T., Abbas, R., Parker, J. C., and Fisher, J. W. Identification of S-(1,2-Dichlorovinyl) glutathione in the blood of human volunteers exposure to trichloroethylene Toxicol Environ. Health 56: 1-21, 1999.
  48. Gu, Z., Tata, P. Zhou, D., Abbas, R., Wu, J., Lewis, N. J., and Bramer, S. L. Sensitive and specific LC-MS/MS method for the analysis of low levels of OPC-29030 and ten metabolites in human plasma and urine. Pharm. Sci.  Vol. 1, No. 1,  s-189,  1998.
  49. Abbas, R., Bramer, S. L., Cowart, D., Adeyemo, O. M., Kitani, M., Miyamoto, G., and Browder, N. J. Interspecies Comparison of TOBORINONE Pharmacokinetics in Rats, Rabbits, Dogs, Monkeys, and Humans. Toxicological Sciences, vol. 42, No.1-S, p216, 1998.
  50. Adeyemo, O.M., Abbas, D. Sibley, R. Mailman, R. Wilcox, T. Kikuchi, T. Hirose, and N. J. Browder, OPC-14597: Unique pharmacology and receptor binding characterization studies on a novel antipsychotic agent, The Toxicologist, 42, No. 1215, p. 246, 1998.
  51. Abbas, R., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D., and Browder, N. J. In vitro metabolism of toborinone by human liver cytochrome P450 isoforms.  Toxicology Letters, vol. 95, S1, p101, 1998.
  52. Fisher, J.W., Mahle, D. and Abbas, R. A Human Physiologically Based Pharmacokinetic Model for Trichloroethylene and its Metabolites, Trichloroacetic Acid and Free Trichloroethanol. Toxicol. Appl. Pharm. 152, 339-359, 1998.
  53. Browder, N. J., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D., and Abbas, R. EFFECT OF TOBORINONE ON HUMAN LIVER CYTOCHROME P450 ISOFORMS  AND INTERACTION  WITH THEOPHYLLINE. Toxicological Sciences, vol. 42, No.1-S, p91, 1998.
  54. Fu, C. J., Abbas, R., Tata, P. N. V., Cowart, C., Bramer, S. L. AN HPLC METHOD FOR THE ANALYSIS OF TOBORINONE (OPC-18790) AND FOUR METABOLITES IN HUMAN PLASMA.  Toxicological Sciences, vol. 42, No.1-S, p219, 1998.
  55. Abbas, R. Tata, P. Bramer, S. L.  Li, Y. X. Heitkamp, J.  and Velagaleti, P.  A SENSITIVE AND SPECIFIC CHIRAL HPLC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Pharm. Res. Vol. 14, No. 11,  s-360,  1997.
  56. Abbas, R. Browder, N. J. Chow, P. Odomi, M. and Bramer, S. L. INTERSPECIES COMPARISON OF CILOSTAZOL PHARMACOKINETICS IN MICE, RATS, DOGS, MONKEYS, AND HUMANS. Pharm. Res. Vol. 14, No. 11,  s-360,  1997.
  57. Moghaddam, A. P., Abbas, R., Fisher, J. W, and Lipscomb, J. C. The role of mouse intestinal microflora in the metabolism of Trichloroethylene, an In Vitro Study.Human and Experimental Toxicology. 16, 629-635. 1997.
  58. Fu, C. J., Abbas, R. Tata, P. Chow, P. Browder, N. J. and Bramer, S. L. An HPLC method for the analysis of toborinone and four metabolites in human liver microsomal incubation solutions. Pharm. Res. Vol. 14, No. 11, s-566,  1997.
  59. Abbas, R., Seckel, C. S., Kidney, J. K., and  Fisher, J. W. PHARMACOKINETIC ANALYSIS OF CHLORAL HYDRATE AND ITS METABOLISM IN B6C3F1 MICE. Drug Metabolism and Disposition. Vol. 24, No. 12 p 1340-1346. 1996.
  60. Abbas, R., and Fisher, J. W. A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice.  Appl. Pharm.  127, 15-30, 1997.
  61. Abbas, R. and W. L. Hayton. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Paraoxon in Rainbow Trout.  Appl. Pharmacol., 145, 192-201, 1997.
  62. Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L. Toxicokinetics of Parathion and Paraoxon in Rainbow Trout after Intravascular Administration and Water Exposure.  Appl. Pharmacol.  136, 194-199, 1996.
  63. Abbas R., and Hayton W L. Gas Chromatographic Determination of Parathion and paraoxon in fish plasma and tissues. Journal of Analytical Toxicology, Vol. 20, 151-154, 1996.
  64. Moghaddam, A. P., Abbas, R., Fisher, J. W., Stavrou, S., and Lipscomb, J. C. Formation of dichloroacetic acid by rat and mouse gut microflora, an in vitro study.  Biophys. Res. Comm.  228, 639-645, 1996.
  65. W. T., Bishop, C. T., and Abbas, R. Electrospray analysis of biological samples for trace amounts of trichloroacetic acid, dichloroacetic acid and monochloroacetic acid.  J. of Anal. Tox.  21, 330-334, 1997.
  66. Abbas, R., Seckel, C. S. and Fisher, J. W.: Determination of kinetic rate constants for chloral hydrate, trichloroethanol, trichloroacetate and dichloroacetate: a PBPK model approach. The Toxicologist, vol. 36, No. 1, 164, 1997.
  67. Fisher, J. W , J. D. Pleil, MacMahon, K. L. and Abbas, R.: A Physiologically Based Pharmacokinetic Model for inhalation of trichloroethylene in human volunteers. The Toxicologist, vol. 36, No. 1, 163, 1997.
  68. Greenberg, M.S. Abbas, R. and Fisher, J. W: A Physiologically Based Pharmacokinetic Model for inhaled trichloroethylene and its major metabolites in B6C3F1 mice. The Toxicologist, vol. 36, No. 1, 162, 1997.
  69. Geiss, K. T., Young, R. S., Randall, G., Kidney, J. K. Channel, S. R. and Abbas, R.: Induction of Peroxisome Proliferation-Associated genes after administration of Trichloroethylene to Mice. The Toxicologist, vol. 36, No. 1, 1185, 1997.
  70. Bishop, C. T., Brashear, W. T., Pollard, D. L., and Abbas, R.: Analysis of Trichloroethylene in Biological Samples. The Toxicologist, vol. 36, No. 1, 1630, 1997.
  71. Zhang, H. M, Brashear, W. T., Buttler, G. T., Callaghan, P. Black, R. and Abbas, R. : An Electron Capture Gas Chromatography Method for Analysis of Dichloroacetic Acid, Trichloroacetic Acid and Trichloroethanol in Biological Matrices. The Toxicologist, vol. 36, No. 1, 1631, 1997.
  72. Lipscomb, J.C., Black, R.K., Janicki, T. J., Mahle D. A., Fisher, J. W. and Abbas, R.: Destruction of Cytochrome P450 in Vitro by Trichloroethylene: Loss of CYP3A and CYP1A Activity. The Toxicologist, vol. 36, No. 1, 1610, 1997.
  73. Moghaddam, A. P., Abbas, R., Fisher, J. W, Stavrou, S. and Lipscomb, J. C.  Metabolism of Trichloroethylene and Trichloroacetic Acid by Mouse Gut Microflora, an In Vitro Study.  The Toxicologist, vol. 36, No. 1, 1610, 1997.
  74. Abbas, R., Fisher, J. W. Black, R. K. and Garrity, B. L.  A Physiologically Based Pharmacokinetic Model to Describe Disposition of Chloral hydrate and Trichloroethanol in Mice.   The International Toxicologist, 1995, 33-20.
  75. Hayton, W L, Yu. Z., Abbas, R., Vick, A. and Doddapaneni, S.  Pharmacokinetics of Acriflavine in Rainbow Trout. The International Toxicologist, 1995, 89-16.
  76. Abbas, R., Fisher, J. W., Black, R. K., Janicki, T. J. and Garrity, B. L. Disposition of Trichloroethylene and Its Metabolites in B6C3F1 Mice after Oral Administration.   Res. Vol. 12, No. 9,  pp. s-338. 1995.
  77. Abbas, R. and Hayton, W. L., 1993. Paraoxon Tissue Distribution and AChE Inhibition in Rainbow Trout.   Res. Vol. 10, No. 10, s-365.
  78. Doddapaneni, S., Hayton, W. L., Schultz, I. R. and Abbas, R., 1993. Tissue Distribution and Metabolic Disposition of Parathion in Rat. Pharm. Res. Vol. 10, No. 10, s-365.
  79. Doddapaneni, S., Herzberg, U., Schultz, I.R. and Abbas, R. and Hayton, W.L., 1992. Parathion and Paraoxon Pharmacokinetics and AChE Inhibition in Rat. Res. Vol. 9, No.10,s 268.
  80. Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L., 1992. Pharmacokinetics of Paraoxon in Rainbow Trout.  The Toxicologist, 12:1554.

CONFERENCE PAPERS:

  1. Richat Abbas, Ann Childress, Praneeta Nagraj, Richard Rolke, Sally A. Berry, Donna Palumbo. Pharmacokinetics and Relative Bioavailability of an Extended-Release Chewable Tablet of Methylphenidate When Chewed Versus Swallowed Whole: A Pilot Study in Healthy Subjects. Presented at the 2017 APSARD Annual Meeting, January 13-15, 2017, Washington D.C
  2. Richat Abbas, PhD; Donna Palumbo, PhD; Faith Walters, PharmD; Heidi Belden, PharmD; Sally A. Berry, MD, PhD. Single-Dose Pharmacokinetics and Relative Bioavailability of a Novel Methylphenidate Extended-Release Chewable Tablet Compared With Immediate-Release Methylphenidate Chewable Tablet. Presented at the American Professional Society of ADHD and Related Disorders; January 15-17, 2016; Washington, D.C.
  3. Richat Abbas, Donna Palumbo, Faith Walters, Heidi Belden, Sally A. Berry. Single-Dose Pharmacokinetics and Relative Bioavailability of a Novel Methylphenidate Extended-Release Chewable Tablet Compared With Immediate-Release Methylphenidate Chewable Tablet. 2015 Annula Meeting of American Academy of Child & Adolescent Psychiatry. October 26–31, 2015. San Antonio, TX
  4. Nicholas, B.Damle, K. Albert, and R. Abbas. Population Pharmacokinetic/Pharmacodynamic Analysis of a Novel Formulation of Methylphenidate. American College of Clinical Pharmacology’s Global Conference on Clinical Pharmacy, October 17–21, 2015, San Francisco, California.
  5. Ira Jacobs, Jennifer Coiro, Fiona Hilton, John Orazem, Richat Abbas, and Charles Zacharchuk. A Phase 3 randomized, double-blind trial comparing PF-05280014 + docetaxel and carboplatin vs. trastuzumab + docetaxel and carboplatin for neoadjuvant treatment of operable HER2[sup]+[/sup] breast cancer. 2014 San Antonio Breast Cancer Symposium, December 9- 13, 2014, San Antonio, Texas. Cancer Research 05/2015; 75(9 Supplement): OT3-1-02-OT3-1-02. DOI:10.1158/1538-7445.SABCS14-OT3-1-02
  6. Ono, P. Hsyu, R. Abbas, C. Loi, S. Yamazaki. APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DRUG INTERACTIONS AS CYP3A SUBSTRATE. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March 3-7, 2015, New Orleans, LA. Clincial Pharmcology & Therapeutics. Volume 97, issue S1 2015, PII-051
  7. Ono, P. Hsyu, R. Abbas, C. Loi, S. Yamazaki. APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DISEASE INTERACTION IN ORGAN DYSFUNCTION PATIENTS. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March 3-7, 2015, New Orleans, LA. Clincial Pharmcology & Therapeutics. Volume 97, issue S1 2015, PII-052
  8. R Abbas, RL Hill, J Salageanu, RR LaBadie, B Damle. An Open-Label, Randomized, Crossover, Bioavailability Study of Depo®-Testosterone Administered by an Auto-Injector versus Manual Injection in Hypogonadal Males. American Association of Pharmaceutical Scientists Annual Meeting, November 2–6, 2014, San Diego, CA. https://2014aapsam.zerista.com/poster/member/21998
  9. Richat Abbas, Sari Alon, Glen Park, DrewLewis, Bharat Damle, and Raul Chertkoff. Pharmacokinetics of novel plant cell-expressed taliglucerase alfa in adult and pediatric patients with Gaucher disease” Molecular Genetics and Metabolism 111 (2014) S15–S96. http://www.sciencedirect.com/science/journal/10967192/111/2.   10th Annual Lysosomal Disease Network World Symposium, February 10-13, 2014, San Diego, CA
  10. Richat Abbas, Bruce Hug, Cathie Leister, Daryl Sonnichsen. A Clinical Study to Assess Effect of Rifampin on the Pharmacokinetics (PK) of Neratinib (HKI-272), a pan-ErbB Receptor Tyrosine Kinase Inhibitor, when Administered Concomitantly in Healthy Subjects. Presented at the Annual Meeting of American Society of Clinical Pharmacology and Therapeutics, March 12 – 17, 2012, National Harbor, MD  (Clinical Pharmamacology and Therapeutics, Vol. 91, S. 1, March 2012)
  11. Poe-Hirr Hsyu, Diane Mould, Richat Abbas, Stuart Pearce, Michael Amantea. A Population Pharmacokinetic Model of Bosutinib, Presented at the AACR-NCI-EORTC, International Conference on Molecular Targets and Cancer Therapeutics, Nov. 12 -1 16, 2011, San Francisco, CA
  12. Abbas, B. Hug, C. Leister, J. Burns, and D. Sonnichsen. A Clinical Study to Evaluate the Effect of Multiple Doses of Lansoprazole on the Pharmacokinetics of Bosutinib (SKI-606), a Dual Inhibitor of Src and Abl Tyrosine Kinases, When Administered Concomitantly to Healthy Subjects. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Oct. 23-27, 2011. Washington, DC
  13. Abbas, C. Leister, B. Hug, and D. Sonnichsen. Effect of Multiple Doses of Neratinib on the Pharmacokinetics of Single-dose Digoxin in Healthy Subjects. American Association of Pharmaceutical Scientists (AAPS). Annual Meeting, Oct. 23-27, 2011.  Washington, DC
  14. Abbas R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D. A Clinical Study to Assess Pharmacokinetics and Safety of Neratinib in Subjects with Chronic Hepatic Impairment and Matched Healthy Subjects.  2011 European Multidisciplinary Cancer Congress (ECCO-ESMO),  23-27, 2011. Stockholm, Sweden. http://www.eccocongress.org/ecco_content/ECCO16_AbstractBook/index.html#/378/
  15. Chow,* S. Gupta, D. L. Hershman, R. Epstein, I. Bondarenko, M-L. Vo Van, A. Freyman, Y. Zhao, R. Abbas, A. Awada. Efficacy and Safety of Neratinib (HKI-272) in Combination With Paclitaxel in Her2+ Metastatic Breast Cancer.  Poster Presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, Texas.
  16. Elzbieta Staroslawska, Luc Dirix, Thehang Luu, Véronique Diéras, Luis Manso, Binghe Xu, Junlan Yang, Richat Abbas, Andrew Strahs, Marie-Louise Vo Van, Anna Berkenblit, Valérie Agrapart, Christine Powell, Ahmad Awada. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2+ metastatic breast cancer pretreated with anti-HER2 therapy.  Poster Presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, Texas.
  17. Abbas-Borhan R, Hug BA, Leister C, Burns J, Sonnichsen D. A clinical study to characterize the occurrence of mild-to-moderate diarrhea after administration of neratinib either once daily or twice daily for 14 days. Abstract #454 available at http://www.ecco-org.eu/Conferences-and-Events/EORTC-NCI-AACR-2010/Abstracts-online/page.aspx/2528. Poster 195 presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, November 16-19, 2010.
  18. Abbas-Borhan R, Hug BA, Leister C, Burns J, Sonnichsen D. A single-dose study to evaluate the relative bioavailability and pharmacokinetics of three new tablet formulations, an oral solution, and a reference capsule of bosutinib in healthy subjects. Abstract M1465 available at http://abstracts.aapspharmaceutica.com/pswc2010/Itinerary/login.asp. Poster presented at the International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in New Orleans, Louisiana, USA, November 14-18, 2010.
  19. Abbas-Borhan R, Hug BA, Leister C, Burns J, Sonnichsen D. Assessment of bioequivalence of phase III and commercial formulations of bosutinib tablets in healthy volunteers. Abstract M1466 available at http://abstracts.aapspharmaceutica.com/pswc2010/Itinerary/login.asp. Poster presented at the International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in New Orleans, Louisiana, USA, November 14-18, 2010.
  20. Abbas-Borhan R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D. Evaluation of pharmacokinetics (PK) and safety of bosutinib in patients with chronic hepatic impairment (HI) and matched healthy subjects. Abstract #401 available at http://www.ecco-org.eu/Conferences-and-Events/EORTC-NCI-AACR-2010/Abstracts-online/page.aspx/2528. Presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, November 16-19, 2010.
  21. Richat Abbas, PhD; Poe-Hirr Hsyu, PhD; Joseph Boni, PhD. Pharmacokinetic (PK) assessment of bosutinib (SKI-606) administered orally to patients with advanced solid tumors in a phase 1 study.  Presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, November 16-19, 2010.
  22. Richat Abbas, PhD; Cathie Leister, MS; Christina Coughlin, MD, PhD; Daryl Sonnichsen, PharmD. Evaluation of Neratinib (HKI-272) and Paclitaxel Pharmacokinetics (PK) in Asian and Caucasian Patients with ErbB2+ Breast Cancer: A Phase 1/2 Study of Neratinib in Combination with Paclitaxel. 35th Congress of the European Society for Medical Oncology. Milan, Italy. October 8 – 12, 2010.
  23. Richat Abbas-Borhan, PhD; Inder Chaudhary, PhD; Joel Kantrowitz, PhD, Bruce A. Hug, MD, PhD; Cathie Leister, MS; Jaime Burns, BS; Daryl Sonnichsen, PharmD. An Open-Label Study to Assess the Mass Balance and Metabolic Disposition of an Orally Administered Single Dose of 14C-Labeled Neratinib, an Irreversible pan-ErbB inhibitor, in Healthy Subjects. Presentation at the 9th International ISSX (International Society for the Study of Xenobiotics)  Meeting (www.issx2010.org) in Istanbul, Turkey September 4 – 8, 2010.
  24. Richat Abbas-Borhan, PhD; Inder Chaudhary, PhD; Bruce A. Hug, MD, PhD; Cathie Leister, MS; Jaime Burns, BS; Sarvesh Vashishtha, PhD; John C.L. Erve, PhD; Daryl Sonnichsen, PharmD. Mass Balance, Metabolic Disposition, Metabolite Characterization, and Pharmacokinetics of Oral 14C-Labeled Bosutinib in Healthy Subjects. Presentation at the 9th International ISSX (International Society for the Study of Xenobiotics)  Meeting (www.issx2010.org) in Istanbul, Turkey September 4 – 8, 2010.
  25. Richat Abbas, Bruce A. Hug, Cathie Leister, Jaime Burns, and Daryl Sonnichsen. A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Bosutinib (SKI-606) on Cardiac Repolarization in Healthy Adult Subjects.  Presented at the Annual Meeting of the European Hemotogy Assciation, June 9-13. 2010, Barcelona, Spain.
  26. Abbas, J. Boni, B. Hug, C. Leister, J. Burns, D. Sonnichsen. Evaluation of the Effect of Rifampin on the Pharmacokinetics (PK) of Bosutinib (SKI-606), a Dual Inhibitor of Src and Abl Tyrosine Kinases, When Administered Concomitantly to Healthy Subjects. Presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 17-20, 2010, Atlanta, GA
  27. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen. Assessment of the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics (PK) of Bosutinib (SKI-606), a Dual Inhibitor of Src and Abl Tyrosine Kinases, in Healthy Subjects. Presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 17-20, 2010, Atlanta, GA
  28. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen. Ascending Single-Dose Study of Safety, Tolerability, and Pharmacokinetics of Bosutinib (SKI-606) in Healthy Subjects. Presented at the AACR-EORTC-NCI Meeting, November 15-19, 2009, Boston, MA
  29. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen. Single-Ascending-Dose Study of Safety, Tolerability, and Pharmacokinetics of Neratinib (HKI-272) in Healthy Subjects. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists, Nov. 08 – 12, 2009, Los Angeles, CA. AAPS Journal. 2009; 11(S2).
  30. Abbas, C. Leister, R. Epstein, C. Coughlin, and D. Sonnichsen. Neratinib and Paclitaxel Pharmacokinetics in the Chinese Patient Population in the Phase 1/2 Study of Neratinib in Combination with Paclitaxel in Patients with Solid Tumors and ErbB2+ Breast Cancer. Presented at the Annual Meeting of the Chinese Society of Clinical Oncology, October 14-18, 2009, Xiamen, China
  31. El Gaaloul, R. Abbas, B. Hug, C. Leister, S. Chalon,1 D. Sonnichsen. Ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib administered orally with multiple doses of ketoconazole to healthy adult subjects.   34h Congress of the European Society for Medical Oncology.  Berlin, Germany, September 20-24, 2009.   Eur J. Cancer Suppl. 2009. &. Abstract P-1239.
  32. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen. A Drug Interaction Study to Evaluate the Effect of Ketoconazole on the Pharmacokinetics (PK) of Neratinib in Healthy Subjects. Presented at the Annual Meeting of American Society of Clinical Pharmacology and Therapeutics, March 18 – 22, 2009, National Harbor, MD
  33. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen Effect of Ketoconazole on the Pharmacokinetics (PK) of Bosutinib (SKI-606) in Healthy Subjects.  Presented at the Annual Meeting of American Society of Clinical Pharmacology and Therapeutics, March 18 – 22, 2009, National Harbor, MD
  34. Chow, Z. Jiang, R. Epstein, I. Bondarenko, A. Awada, C. Coughlin, E. Gauthier, Y. Zhao, R. Abbas, D. Hershman. Safety and Efficacy of Neratinib (HKI-272) in Combination With Paclitaxel in Patients With Solid Tumors.   Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition).  Vol 27, No 15S (May 20 Supplement), 2009: 3557.
  35. Swaby; K. Blackwell; Z. Jiang; Y. Sun; V. Dieras K. Zaman; C. Zacharchuk; C. Powell; R. Abbas; M. Thakuria. Neratinib in Combination With Trastuzumab for the Treatment of Advanced Breast Cancer: A Phase 1/2 Study.    Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition).  Vol 27, No 15S (May 20 Supplement), 2009: 1004.
  36. Daud, S. Krishnamurthi, B. Hewes, C. Zacharchuk, R. Abbas, P. Martins, E. Dowling, A. Volkert, E. Martin, W. Messersmith. Bosutinib, a Dual Src/Abl Tyrosine Kinase Inhibitor: Preliminary Results from a Phase 1 Study in Patients With Advanced Malignant Solid Tumors. Presented at the 43rd American Society of Clinical Oncology Annual Meeting June 1-5, 2007. Chicago, Illinois.  Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007.
  37. Gambacorti-Passerini, T.H. Brümmendorf, H. Kantarjian, M. Baccarani, D. Liu, T. Fisher, B. Hewes, A.D.G. Volkert, R. Abbas, J. Cortes. Bosutinib Exhibits Clinical Activity in Patients with Philadelphia Chromosome Positive CML or ALL Patients who Failed Imatinib.  Presented at the 43rd American Society of Clinical Oncology Annual Meeting June 1-5, 2007. Chicago, Illinois.  Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7006
  38. H. Brümmendorf, J. Cortes, H. Kantarjian, G. Martinelli, D. Liu, T. Fisher, B. Hewes, A.D.G. Volkert, R. Abbas, C. Gambacorti-Passerini. SKI-606 exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib. Presented at 2007 Annual Meeting of European Society of Hematology, 7-10 June 2007, Vienna, Austria.
  39. Cortes, H. Kantarjian, M. Baccarani,  T.H. Brümmendorf,  D. Liu,  G. Ossenkoppele,  A.D.G. Volkert, BA, B. Hewes, L. Moore,  R. Abbas,  C. Zacharchuk,  and C. Gambacorti-Passerini.  A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib (ALL).  Presented at The American Society of Hematology, 48th Annual Meeting and Exposition, Dec. 9-12, 2006, Orlando, FL. Blood (ASH Annual Meeting Abstracts) 2006. 108:  Abstract 168.
  40. K. Wong, P. M. Fracasso, R. M. Bukowski, P. N. Munster, T. Lynch, R. Abbas, S. E. Quinn, C. Zacharchuk, H. Burris. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors.  Journal of Clinical Oncology, (2006 ASCO Annual Meeting Proceedings) Part I. Vol 24, No. 18S (06-20 S.), 2006: 3018
  41. Folprecht, J. Tabernero, L. Paz-Ares, J. Baselga, H. Cortes-Funes, E. Casado, F. Rojo, J. Vauthier, Richat Abbas, C. Zacharchuk, C. Koehne. The irreversible EGFR tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (ACC): A phase I/IIa pharmacokinetic and serial skin and tumor pharmacodynamic study.  29th European Society for Medical Oncology (ESMO) Congress. Oct. 29 – Nov. 2, 2004, Vienna, Austria.
  42. Abbas, J. Boni, C. Leister, K. Saluti, S. Quinn, C. Zacharchuk. Evaluation of Pharmacokinetic Interactions Between EKB-569, an Irreversible Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase, and Gemcitabine in Patients With Advanced Pancreatic Cancer.  2004 AAPS Annual Meeting and Exposition, November 7-11, 2004, Baltimore, Maryland
  43. R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker. Effect of R411, a Dual 4/1-4/7 Integrin Antagonist Being Developed for Asthma, on the Activities of the Major Drug Metabolizing Enzymes After Oral Administration in Healthy Subjects  Presented at the 2004 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics,  March 24-27, 2004, Maimi Beach, FL
  44. R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker. Safety, Tolerability, and Pharmacokinetics of R411, a Dual 4/1-4/7 Integrin Antagonist, after Oral Administration of Single-Ascending Doses in Healthy Male Subjects. Presented at the 2004 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, March 19 – 23, 2004, San Francisco, CA
  45. Abbas, Y. Hijazi, J. P. Tang, L. M. Renzetti, A. Rames and H. Welker. Safety, Tolerability and Pharmacokinetics of R411, a Dual 4/1 and 4/7 Integrin Antagonist after Multiple-ascending Doses in Healthy Subjects. Presented at the 2004 International Conference of the American Thoracic Society.  May 21-26, 2004, Orlando, FL
  46. Richat Abbas, Scott Fettner, Myriam Riek, Sunita Bulsara, Michael Pantze, Marta Hamilton, Paul Frohna, and Ashok Rakhit A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, TarcevaTM, in healthy subjects.   American Society of Clinical Oncology, May 31 – June 3, 2003 Chicago, IL
  47. Kapitza, E. Arbit, R. Abbas, M. Goldberg, M. Hompesch, L. Heinemann, T. Heise, Oral Insulin: Proof of concept in type 2 diabetic patients. 18th International Diabetes Feration Congress, Aug. 24-29, 2003, Paris, France.
  48. Richat Abbas, Scott Fettner, Myriam Riek, Steve Davis, Marta Hamilton, Paul Frohna, and Ashok Rakhit. Effect of ketoconazole on the pharmacokinetics of erlotinib (TARCEVATM) in healthy adult male subjects. European Association of Clinical Pharmacology and Therapeutics (EACPT), June 24-28, 2003. Istanbul, Turkey
  49. Ashok Rakhit, Scott Fettner, Stephen Davis, Richat Abbas, Flavio De Rosa, Ulrich Brennscheidt, Chis Twelves and Jose Baselga. Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients.  Presented at the 12th annual Meeting of the Federation of European Cancer Society (ECCO-12), Sept. 21-25, 2003, Copenhagen, Denmark
  50. Ashok Rakhit, Scott Fettner, Myriam Riek, Stephen Davis, Marta Hamilton, Paul Frohna, Richat Abbas. Clinical pharmacokinetics of  erlotinib in healthy subjects. Presented at the 12th annual Meeting of the Federation of European Cancer Society (ECCO-12), Sept. 21-25, 2003, Copenhagen, Denmark.
  51. Ehud Arbit MD, Richat Abbas PhD, Steve Dinh PhD and Michael Goldberg MD. The potential clinical implications of the pharmacokinetic profiles of insulin administered by alternate routes. Presented at the 2002 Diabetes Technologies Annual Meeting, Nov. 2002, Atlanta, GA
  52. Richat Abbas, Andrea Leone-Bay, Rajesh Agawal, Shingai Majuru, Paul Rolan, Cyril Clarke, Colin Scott,Ehud, Arbit¬, Robert A. Baughman – Oral Insulin: Pharmacokinetics and Pharmacodynamics of Human Insulin Following Oral Administration of an Insulin/Delivery Agent Capsule in Healthy Volunteers – Presentation at the 62nd Annual Meeting American Diabetes Assciation, June 14-16, 2002, San Francisco, CA
  53. Richat Abbas, Robert A. Baughman, S. De Bruyn, Donald Sarubbi, and Ehud Arbit – Oral Cromolyn: Pharmacokinetics of Cromolyn Sodium Delivered Orally in Healthy Volunteers – Presentation at the the XXI Congress of the European Academy of Allergology and Clinical Immunology, 1-5 June 2002, Naples, Italy.
  54. Richat Abbas, Rajesh Agarwal, Terry Rivera-Schaub, Andrea Leone-Bay, Kiran Chaudhary, and Robert A. Baughman – Evaluation of the Effect of Three Different Oral Heparin/SNAC Formulations on Pharmacokinetics (PK) of Heparin Following Oral Administration in Healthy Subjects.  Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Nov. 10-14,  2002, Toronto, Canada
  55. Richat Abbas, Robert A. Baughman, de Vries, Steve Dinh and, Ehud Arbit – Pharmacokinetics of Human Insulin Delivered Orally in Healthy Volunteers – Presented at the Diabetes Technologies Meeting, (This was accepted as a best abstract and presented at Diabetes Technologies Meeting).  Nov. 2-3, 2001, San Francisco.
  56. Richat Abbas, A. Chaouki Zerouala, and Robert A. Baughman. PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SNAD/HEPARIN IN RHESUS MONKEYS. Presented at the 6th ISSX Annual Meeting, October 7-11, 2001, Munich, Germany
  57. Richat Abbas, Alda Pombo-Gentile, and Robert A. Baughman. Absolute bioavailability of SNAD and Pharmacokinetics of SNAD/heparin in rats.  Presented at the 6th ISSX Annual Meeting, October 7-11, 2001, Munich, Germany.
  58. Richat Abbas, Gregory Osgood, Terry Rivera-Schaub, James C. Kisicki, and Robert A. Baughman. A Clinical Drug-interaction Study to Evaluate Effect of Antacid Pre-treatment on the Absorption of Heparin and its Delivery Agent, SNAC, Following Oral Administration in Healthy Subjects. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Oct.  2001, Denver, CO.
  59. Richat Abbas, Andrea Leone-Bay, Terry Rivera-Schaub, Shingai Majuru, James C. Kisicki, and Robert A. Baughman. An Open-label, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SNAD, an Oral Heparin Delivery Agent, when Administered Orally as SNAD Tablets or Heparin/SNAD Tablets to Healthy Male Volunteers. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Oct.  2001, Denver, CO.
  60. Richat Abbas, Theresa Rivera-Schaub, Igor Rubets, Rajesh Agarwal and Robert A. Baughman. Clinical Pharmacokinetics and Absolute Bioavailability of the Oral Delivery Agent SNAC when Dosed Orally as SNAC/Heparin to Healthy Volunteers.  Presented at the Pharmaceutical Congress of Americas, March 24-29, 2001, Orlando FL.
  61. Andrea Leone-Bay, Theresa Rivera-Schaub, Shingai Majuru, Richat Abbas, James Kisicki, and Robert A. Baughman. PHASE I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF AN ORAL HEPARIN TABLET.  Presented at the American Society of Hematology 2001 Annual Meeting.  December 7 – 11, 2001, Orlando, FL.
  62. Gu, Z., Tata, P. Zhou, D., Abbas, R., Wu, J., Lewis, N. J., and Bramer, S. L. A sensitive and specific LC-MS/MS method for the analysis of low levels of OPC-29030 and ten metabolites in human plasma and urine.  Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists.  15-19.  1998,  San Francisco, CA.
  63. Abbas, R., Bramer, S. L., Cowart, D., Adeyemo, O. M., Kitani, M., Miyamoto, G., and Browder, N. J. Interspecies Comparison of TOBORINONE Pharmacokinetics in Rats, Rabbits, Dogs, Monkeys, and Humans.  Presented at the 37th Annual Meeting of the Society of Toxicology, March 1-5, 1998, Seattle, WA.
  64. Abbas, R., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D., and Browder, N. J. In vitro metabolism of toborinone by human liver cytochrome P450 isoforms. Presented at the 37th Annual Meeting of the Society of Toxicology, March 1-5, 1998, Seattle. WA
  65. Abbas, R. Tata, P. Bramer, S. L.  Li, Y. X. Heitkamp, J.  and Velagaleti, P.  A LC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM.  Presented at the 6th European International Society for the Study of Xenobiotics Meeting, June 30-July 3, 1997, Gothenburg, Sweden.
  66. Abbas, R. Tata, P. Bramer, S. L.  Li, Y. X. Heitkamp, J.  and Velagaleti, P.  A SENSITIVE AND SPECIFIC CHIRAL HPLC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Presented at the 12TH Annual Meeting of  American Association of Pharmaceutical Scientists,  2-6, 1997. Boston.
  67. Abbas, R. Browder, N. J. Chow, P. Odomi, M. and Bramer, S. L. INTERSPECIES COMPARISON OF CILOSTAZOL PHARMACOKINETICS IN MICE, RATS, DOGS, MONKEYS, AND HUMANS. Presented at the 12TH Annual Meeting of  American Association of Pharmaceutical Scientists,    2-6, 1997. Boston.
  68. Abbas, R., Seckel, C. S. and Fisher, J. W.: Determination of kinetic rate constants for chloral hydrate, trichloroethanol, trichloroacetate and dichloroacetate: a PBPK model approach. Presented at the 36th Annual Meeting of the Society of Toxicology, March 9-13, 1997, Cincinnati, OH.
  69. Abbas, J. W. Fisher, R. K. Black, T. J. Janicki, and , K. MacMahan. Development of A Physiologically Based Pharmacokinetic (PBPK) Model for Tricholoroethylene and its Metabolites B6C3F1 Mice. Presented at the  35th  Annual Meeting of the Society of Toxicology, March 10-14, 1996, Anaheim, CA.
  70. Abbas, R., Fisher, J. W. Black, R. K. and Garrity, B. L.  A Physiologically Based Pharmacokinetic Model to Describe Disposition of Chloral hydrate and Trichloroethanol in Mice.   Presented at the International Congress of Toxicology – VII, July 2-6, 1995, Seattle, WA.
  71. Abbas, R., Fisher, J. W., Black, R. K., Janicki, T. J. and Garrity, B. L. Disposition of Trichloroethylene and Its Metabolites in B6C3F1 Mice after Oral Administration.   Presented at the 10TH Annual Meeting of  American Association of Pharmaceutical Scientists,  5-9, 1995.  Miami, FL.
  72. Abbas, R. and Hayton, W. L., In vivo Acetylcholinesterase Inhibition in Rainbow Trout after Water Exposure to Paraoxon.  Presented at the 25th Annual Pharmaceutics Graduate Student Research Meeting, 1993, West Lafayette, Indiana.
  73. Abbas, R. and Hayton, W. L., Paraoxon Tissue Distribution and AChE Inhibition in Rainbow Trout. Presented at the 8TH Annual Meeting of  American Association of Pharmaceutical Scientists, Nov. 14-18, 1993, Lake Vuena Vista, FL.
  74. Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L., 1992. Pharmacokinetics of Paraoxon in Rainbow     Presented at the 31st   Annual Meeting of the Society of Toxicology, Feb. 23-28, 1992, Seattle, WA.

PATENTS:

  1. Abbas, Richat, et al. “Oral insulin therapy”. United States Patent – 20030198666, U.S. Current Class: 424/452; 424/465; 514/3. U.S. Class at Publication: 424/452; 514/3; 424/465. International Class:  A61K 038/28; A61K 009/48; A61K 009/20
  2. Abbas, Richat, et al. “Formulations for Oral administration of Cromolyn Sodium” US Patenet No. 02789934.3-2123 – US0238247

BOOK CHAPTERS:

  1. Creech, J.R., R.K. Black, B.L. Garrity, R.J. Williams, J.N. McDougal, G.W. Jepson, Abbas, L. Dong, and A. Vinegar: Inhalation Uptake and Metabolism of  Iodohalogenated Compounds, CF3I, C6F13I, and C3F7I. AL/OE-TR-1995-0089
  2. Analysis of Biological Materials and Xenobiotics – Enviromental Chemistry, Boca Raton, CRC Press LLC 2000

Uyghur Academy © All Rights Reserved.

Scroll to top